231 related articles for article (PubMed ID: 34477158)
1. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.
Gao J; Li F; Liu Z; Huang M; Chen H; Liao G; Meng J; Wang Q; Zhao H; Li C; Ji J; Cai S; Du N
Medicine (Baltimore); 2021 Sep; 100(35):e27130. PubMed ID: 34477158
[TBL] [Abstract][Full Text] [Related]
2. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in recurrent ovarian cancer.
Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
8. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.
Karihtala P; Mäenpää J; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2010 Mar; 30(3):1001-6. PubMed ID: 20393027
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
11. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
12. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression.
Li J; Yue H; Li W; Zhu G; Zhu T; Chen R; Lu X
J Ovarian Res; 2021 Nov; 14(1):166. PubMed ID: 34802430
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in ovarian cancer: A critical review of phase III studies.
Rossi L; Verrico M; Zaccarelli E; Papa A; Colonna M; Strudel M; Vici P; Bianco V; Tomao F
Oncotarget; 2017 Feb; 8(7):12389-12405. PubMed ID: 27852039
[TBL] [Abstract][Full Text] [Related]
16. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
17. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations.
Hu M; Zhang T; Gu M; Li J; Zhang H; Wang Q; Hu F; Yang Y; Li B
Genet Test Mol Biomarkers; 2020 Dec; 24(12):798-803. PubMed ID: 33347392
[No Abstract] [Full Text] [Related]
19. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
